Phase ii intraperitoneal rhIL 12
Phase ii intraperitoneal rhIL 12
批准号:
6340132
负责人:
RALPH Stuart FREEDMAN
金额:
$30.75万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-05-01 至 2003-04-30
关键词:
apoptosis drug adverse effect enzyme linked immunosorbent assay fibroblast growth factor human subject human therapy evaluation interferon gamma interleukin 10 interleukin 12 interleukin 2 interleukin 5 interleukin 8 intraperitoneal injections minimal residual disease neoplasm /cancer immunology neoplasm /cancer immunotherapy ovary neoplasms patient oriented research pharmacokinetics quality of life recombinant proteins tumor antigens tumor necrosis factor alpha vascular endothelial growth factors
中文摘要
描述(由申请人提供):我们的长期目标是开发一个
有效的生物免疫治疗方法,以提高患者的生存
上皮性卵巢癌(EOC)。EOC累及腹盆腹膜
和serepressive表面,并提供了一个适当的目标,腹膜内
(IP)治疗试验重组人白细胞介素-12(rhIL- 12)刺激
自然杀伤细胞活性,并通过激活增强适应性免疫
TH 1淋巴细胞在体外。rhIL-12介导的临床前抗肿瘤作用
动物模型主要涉及肿瘤特异性T细胞和抗血管生成
机制等IL-12分子的大尺寸及其免疫生物学效力
在临床前研究中表明rhIL-12可能具有有用临床,
作为免疫生物制剂,
EOC患者的IP治疗。我们已经确定了
在I期临床试验中IP rhIL-12(Genetics Institute)的毒性(DLT)
每周一次IP注射方案。阶段的药代动力学研究
I临床试验证实IL-12在腹膜液(pf)中持续存在
IP注射后。IFN-γ水平升高,在某些情况下
腹腔注射rhIL- 12后检测TNF-α。此外,减少
促血管生成分子FGF 2和VEGF在腹腔的表达
在较高剂量水平的IP rhIL- 12下检测到肿瘤。的具体目标
根据PA 00 -047的要求,该建议包括:(1)开展II期临床试验
在既往化疗后有微小残留病变的患者中进行的试验,
以300 ng/kg的每周剂量IP rhIL-12,并确定(a)应答率,
(b)无进展生存期,(c)临床毒性,(d)生活质量
(e)对腹膜肿瘤细胞的治疗效果(DNA流动和凋亡),
(f)药物动力学。(2)确定IP rhIL-12的药效学,
它是否促进体内适应性或先天性免疫,由(a)证明,
治疗后细胞因子谱的变化表明TH 1型应答(tIL 2,
(up箭头)IFN-g(向上箭头)TNF-α)或TH 2型应答((向上箭头)IL-5,(向上箭头
箭头)IL-10)或NK细胞应答((向上箭头)IFN-g)&患者是否
(B)确定IP应答是否与特定的细胞因子谱相关;
rhIL- 12导致外周血IFN-γ产生增加
淋巴细胞或腹膜渗出物T细胞或细胞水平的NK细胞;
(3)确定IL-12是否促进对肿瘤的血清抗体应答
相关抗原的EOC细胞上的免疫印迹分析。(四)
确定促血管生成因子VEGF、FGF 2和IL-8的表达是否与血管生成相关。
在IF rhIL- 12之后降低。
英文摘要
DESCRIPTION (Provided by applicant): Our long-term goal is to develop an
effective bioimmunotherapy approach to improve the survival of patients with
epithelial ovarian carcinoma (EOC). EOC involves the abdominopelvic peritoneum
and serosal surfaces, and provide an appropriate target for intraperitoneal
(IP) therapy trials. Recombinant human interleukin- 12 (rhIL- 12) stimulates
natural killer cell activity and enhances adaptive immunity through activation
of TH1 lymphocytes in vitro. rhIL-12 mediated antitumor effects in preclinical
animal models primarily involve tumor specific T cells and antiangiogenic
mechanisms. The large size of the IL-12 molecule and its immunobiologic potency
in preclinical studies suggest that rhIL-12 could have useful clinical,
pharmacologic and pharmacodynamic effects as an immunobiological agent in the
IP treatment of patients with EOC. We have determined the dose limiting
toxicity (DLT) of IP rhIL-12 (Genetics Institute) in a phase I clinical trial
in a once weekly IP injection schedule. Pharmacokinetic studies from the phase
I clinical trial demonstrated persistence of IL-12 in peritoneal fluid (pf)
after IP injection. Increased pf levels of IFN-gamma and in some instances
TNF-a, were detected after IP injection of rhIL- 12. Furthermore, decreased
expression of the proangiogenic molecules FGF2 and VEGF on peritoneal cavity
tumor was detected at higher dosing levels of IP rhIL- 12. The specific aims of
this proposal in response to PA00-047 are: (1) To conduct a phase II clinical
trial in patients with minimal residual disease after one prior chemotherapy,
with IP rhIL-12 at a weekly dose of 300 ng/kg, and determine (a) response rate,
(b) progression-free survival, (c) clinical toxicity, (d) quality of life
profiles, (e) therapy effects on peritoneal tumor cells (DNA flow & apoptosis),
& (f) pharmacokinetics. (2) Determine pharmacodynamics of IP rhIL-12 and
whether it facilitates adaptive or innate immunity in vivo evidenced by (a)
change in posttreatment cytokine profiles indicating a TH1 type response (tIL2,
(up arrow) IFN-g (up arrow) TNF-a) or TH2 type response ((up arrow) IL-5,(up
arrow) IL-10) or NK cell response ((up arrow) IFN-g) & whether patient
responses correlate with a specific cytokine profile; (b) Determine whether IP
rhIL- 12 results in increased production of IFN-g by peripheral blood
lymphocytes or peritoneal exudate T cells or NK cells at the cellular level;
(3) Determine whether IL-12 facilitates serum antibody responses to tumor
associated antigens on EOC cells utilizing immunoblotting analysis. (4)
Determine whether expression of proangiogenic factors VEGF, FGF2 and IL-8 are
decreased following IF rhIL- 12.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Autologous therapeutic tumor vaccine + IFN-gamma
-
批准号:7043650
-
项目类别:
-
资助金额:$0.4万
-
财政年份:2004
-
负责人:RALPH Stuart FREEDMAN
-
依托单位:
Phase ii intraperitoneal rhIL 12
-
批准号:6515120
-
项目类别:
-
资助金额:$27.0万
-
财政年份:2001
-
负责人:RALPH Stuart FREEDMAN
-
依托单位:
B7.1 COSTIMULATION IN OVARIAN CANCER
-
批准号:6342153
-
项目类别:
-
资助金额:$14.84万
-
财政年份:2000
-
负责人:RALPH Stuart FREEDMAN
-
依托单位:
B7.1 COSTIMULATION IN OVARIAN CANCER
-
批准号:6046172
-
项目类别:
-
资助金额:$14.41万
-
财政年份:2000
-
负责人:RALPH Stuart FREEDMAN
-
依托单位:
AUTOLOGOUS THERAPEUTIC TUMOR VACCINE + IFN GAMMA IN OVARIAN CANCER
-
批准号:6265671
-
项目类别:
-
资助金额:$1.11万
-
财政年份:1998
-
负责人:RALPH Stuart FREEDMAN
-
依托单位:
IP PRIMING WITH RIFNG AND RIL 2 IN IP ADOPTIVE IMMUNOTHERAPY OF OVARIAN CANCER
-
批准号:6252254
-
项目类别:
-
资助金额:$1.67万
-
财政年份:1997
-
负责人:RALPH Stuart FREEDMAN
-
依托单位:
IP PRIMING WITH RIFNG AND RIL 2 IN IP ADOPTIVE IMMUNOTHERAPY OF OVARIAN CANCER
-
批准号:6281670
-
项目类别:
-
资助金额:$1.36万
-
财政年份:1997
-
负责人:RALPH Stuart FREEDMAN
-
依托单位:
OVARIAN CARCINOMA TIL TREATMENT AFTER IFN GAMMA/IL2
-
批准号:2107694
-
项目类别:
-
资助金额:$18.2万
-
财政年份:1994
-
负责人:RALPH Stuart FREEDMAN
-
依托单位:
OVARIAN CARCINOMA TIL TREATMENT AFTER IFN GAMMA/IL2
-
批准号:2107696
-
项目类别:
-
资助金额:$19.69万
-
财政年份:1994
-
负责人:RALPH Stuart FREEDMAN
-
依托单位:
OVARIAN CARCINOMA TIL TREATMENT AFTER IFN GAMMA/IL2
-
批准号:2107695
-
项目类别:
-
资助金额:$18.93万
-
财政年份:1994
-
负责人:RALPH Stuart FREEDMAN
-
依托单位:
OVARIAN CARCINOMA TIL TREATMENT AFTER IFN GAMMA/IL2
-
批准号:2429829
-
项目类别:
-
资助金额:$20.47万
-
财政年份:1994
-
负责人:RALPH Stuart FREEDMAN
-
依托单位:
IP PRIMING WITH RIFNG AND RIL 2 IN IP ADOPTIVE IMMUNOTHERAPY OF OVARIAN CANCER
-
批准号:6121100
-
项目类别:
-
资助金额:$1.51万
-
财政年份:--
-
负责人:RALPH Stuart FREEDMAN
-
依托单位:
AUTOLOGOUS THERAPEUTIC TUMOR VACCINE + IFN GAMMA IN OVARIAN CANCER
-
批准号:6309235
-
项目类别:
-
资助金额:$1.11万
-
财政年份:--
-
负责人:RALPH Stuart FREEDMAN
-
依托单位:
IP PRIMING WITH RIFNG AND RIL 2 IN IP ADOPTIVE IMMUNOTHERAPY OF OVARIAN CANCER
-
批准号:5224116
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:RALPH Stuart FREEDMAN
-
依托单位:--